The largely heterogeneous course of multiple sclerosis (MS) has been puzzling physicians for decades. Most of the patients (~85%) experience an initial relapsing-remitting (RR) phase, characterized by acute attacks, which can produce temporary or permanent loss of function. However, the conversion to secondary-progressive (SP) MS (SPMS), leading to a relentless accumulation of permanent severe disability and exerting the most significant burden of the disease, is deservedly considered the key determinant of the long-term prognosis. At individual level, the frequency, phenotype, and severity of relapses are extremely variable, and although the risk of entering the SP phase increases proportionally with the disease duration (odds ratio (OR) = 1.07 for each additional year), a substantial percentage of patients can remain free of the progressive course even more than 35 years after the clinical onset. 1 Understanding pathological processes that drive the disease progression and account for the large variability of the clinical phenotype remains a significant challenge. In addition, it is still unexplained why in some patients the progressive course starts de novo (primary-progressive (PP) MS (PPMS)), without being preceded by an RR phase.
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The influence of age on the MS course has been highlighted since the early epidemiological studies. Analyses of several worldwide natural history cohorts provided cogent evidence of remarkably similar mean age at onset of progression, between PPMS and SPMS patients, 1,2 and among progressive MS patients clustered by the total number of relapses preceding the progressive course (mean age at onset of progression: relapsingremitting MS (RRMS) with ⩾4 relapses = 39.2 years, RRMS with 2-3 relapses = 41.4 years, RRMS with 1 relapse = 41.3 years, PPMS = 38.6 years). 3 Based on these observations, Confavreux and Vukusic 2 hypothesized that PPMS is preceded by an "amputated" asymptomatic RR phase and proposed the elegant concept of a unifying disease course, where different MS clinical phenotypes are age dependent, suggesting that the emergence of the progressive phase might just be an effect of age, rather than the effect of a change in the disease pathology.
Indeed, the paucity of MS patients experiencing a progressive course at young age supports the intriguing hypothesis that the development of progressive MS is predominantly a matter of growing older. MS pediatric patients very rarely present with a PP course, and despite their very young age at RR onset, they tend to enter the SP phase in adult age. 4 The probability of converting to SPMS was shown to increase proportionally with current age becoming older (OR = 1.06 for each additional year), independently of the disease duration. 5 In addition, older age at the onset of the RR phase associates with a higher risk of entering the SP phase and with a shorter latency to progression. 1, 5 Among London Ontario database patients, those 50 years old at the first demyelinating attack were three times more likely to become progressive, in comparison with those 20 years old (ORs = 6.04 and 2.05, respectively), and there was a 10 years mean difference for converting to SPMS, between the groups with young (⩽20 years) and old (>30 years) age at onset (mean time to SPMS = 25.8 and 15.3 years, respectively). 5 Certainly, the minority of MS patients who avert the progressive phase, despite their old age, can be considered outliers with a truly benign disease course.
In line with evidence of axonal loss and brain atrophy at the earliest stage of RRMS, 6 the similar mean age at onset of progression, between PPMS and SPMS patients, suggests that neurodegenerative mechanisms are active much before the occurrence of the progressive course and gradually become clinically evident by growing older. Observations from subjects with radiologically isolated syndrome (RIS) confirmed that the clinical onset of PPMS is preceded by a prodromal phase of asymptomatic disease activity with variable duration. 7 Therefore, the subclinical degeneration gradually emerges under the influence of age, probably in the context of exhaustion of the brain reserve capacity and of repair mechanisms. 8 The initial focal inflammatory insult slowly subsides, but it is then chronically amplified by additional age-dependent mechanisms, leading to iron deposition, which accumulate in the microglia and around slowing expanding MS progression is predominantly driven by age-related mechanisms -YES lesions, sustaining the oxidative injury, the mitochondrial dysfunction, and ultimately the continuous accumulation of brain damage. 8 The association between vascular comorbidities and disability accumulation further emphasizes the role of age-related mechanisms in determining the disease progression.
These pathophysiological hypotheses plausibly explain the relationship between growing older and the onset and the evolution of progressive MS. However, age also influences the disease clinical manifestations before the occurrence of the progressive phase. Being older at clinical onset associates not only with a shorter duration of the RR phase but also with a lower number of relapses. Among older patients, the pre-progressive disease course is more often characterized by sparse and infrequent clinical attacks. 3 Similarly, progressive MS patients are more likely to experience overlapping relapses and gadolinium-enhancing lesions at young age. 1,2 Overall, the annualized relapse rate gradually decreases with growing older (by approximately 2% per year), 3 implying a converse relationship between age and the number of inflammatory attacks, which is in line with pathological 8 evidence of an age-dependent decline of the focal inflammatory activity. Intriguingly, older age at detection of RIS is associated with increased probability of developing PPMS rather than RRMS, 7 further indicating that age influences the occurrence of relapses. Whether subjects with RIS, who eventually develop a PP course, do not experience clinical relapses before progression, because of their older mean age, remains a speculative hypothesis. However, data indicate that the younger the age at conversion from RIS to clinically isolated syndrome, the higher is the probability of presenting with a relapsing course characterized by frequent inflammatory attacks. In addition, age affects the phenotypic features and the severity of relapses. By growing, older patients are more likely to experience incomplete recovery following relapses and inflammatory attacks at old age are more frequently characterized by motor and cerebellar symptoms, 9 which are the common clinical features of the progressive phase.
Taken together, evidence defines a unified disease model, with a widely variable age-related pre-progressive clinical phenotype. At one end of this spectrum lie patients with clinical onset at young age, displaying a predominantly inflammatory disease course, with long duration of the RR phase and frequent inflammatory attacks. On the opposite end are patients older at onset, experiencing shorter latency to progression and less relapses. The regulatory effect of age on biological mechanisms leading to the onset of the SP phase and governing the frequency and the severity of relapses suggests an interaction between the neurodegenerative processes and the clinical acute exacerbations. It is plausible to hypothesize that by growing older the subclinical progression gradually prevails on the focal inflammation, tempering acute inflammatory attacks and altering their clinical expression.
The occurrence of a more florid inflammatory activity at young age reasonably explains the age-dependent efficacy of disease-modifying treatments (DMTs), which have been consistently shown to exert a better control of the disease activity, among younger patients. 10 Therefore, patients' age should be considered in the therapeutic decision-making process, as the use of DMTs, among old patients with stable disease, might be unnecessary. In addition, as currently used broad age inclusion criteria (18-55 years) in clinical trials can potentially account for the variation of the disease progression, randomization should control more carefully for age bias. Finally, the inverse relationship between age and relapsing activity weakens the validity of the frequency of inflammatory attacks, as indicator of the disease evolution across wide age ranges.
To conclude, the complex interplay between inflammation and axonal loss drives the accumulation of disability. When and if the neurodegenerative processes dissociate from the gradually declining and compartmentalized inflammatory activity 8 is a question that lies at the core of an endless debate in the MS scientific community. Certainly, considering progressive MS a strictly age-dependent neurodegenerative disease would be an oversimplification, as at the individual level the age at onset of progressive MS varies considerably, 3 accounting for the large inter-individual variability of the outcome. However, evidence here discussed strongly suggests that the disease phenotype gradually converges into a progressive course under the dominant influence of age-related pathological processes. Efforts should be focused on the identification of these complex mechanisms that might become the target of future treatments.
Acknowledgements
The author would like to thank Professor R Nicholas, Professor P Muraro, and Dr M Mattoscio for their valuable comments.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article. 
ORCID iD

MS progression is predominantly driven by age-related mechanisms -NO Marisa McGinley and Daniel Ontaneda
Progression in multiple sclerosis (MS) is a pathologically complex process that encompasses several features including central nervous system atrophy, loss of tissue integrity, and clinical worsening. Although overt clinical progression often manifests later in life and with longer disease duration, there is a large body of evidence that demonstrates that neurodegeneration occurs practically from disease onset. The ability to detect clinical progression in studies and in the office may also be limited, as most definitions use a confirmed change in the Expanded Disability Status Scale (EDSS) to determine disease progression. Scales such as the EDSS may be a relatively blunt measure of actual disease progression. It is however not uncommon for patients to report progression in fatigue, cognitive function, or motor fatigability which is not easily captured or quantified. Age has been implicated as a cause of disease progression but accumulation of tissue injury early in the disease, as measured by accumulation of new T2-weighted lesions and presence of gadolinium-enhancing lesions, is a significant driver of subsequent disease progression. A combination of complex pathophysiological changes, including axonal degeneration, cortical demyelination, cortical neuronal loss, and deep gray matter injury in the first years of the disease, occurs independently of age. Observations from pathology, longitudinal imaging, and pediatric/early disease onset studies demonstrate that early damage is key for the development of progression and that this process is not purely age related.
Pathology study of post-mortem tissue demonstrates that axonal transection and subsequent degeneration occur even in early relapsing-remitting multiple sclerosis (RRMS). 1 In that study, it was suggested that a specific threshold of axonal loss may result in progressive clinical deterioration. Variability in both the amount of axonal loss and compensatory mechanisms may explain why this threshold is reached differently
